Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study-Reference-Cited by-同舟云学术

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study

Published:2020-02 Issue:2 Volume:7 Page:e112-e121
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Owen Roger G,McCarthy Helen,Rule Simon,D'Sa Shirley,Thomas Sheeba K,Tournilhac Olivier,Forconi Francesco,Kersten Marie José,Zinzani Pier Luigi,Iyengar Sunil,Kothari Jaimal,Minnema Monique C,Kastritis Efstathios,Aurran-Schleinitz Thérèse,Cheson Bruce D,Walter Harriet,Greenwald Daniel,Chen Dih-Yih,Frigault Melanie M,Hamdy Ahmed,Izumi Raquel,Patel Priti,Wei Helen,Lee Sun Ku,Mittag Diana,Furman Richard R

Publisher

Elsevier BV

Subject

Hematology

Reference20 articles.

1. Treatment recommendations from the Eighth International Workshop on Waldenstrom's macroglobulinemia;Leblond;Blood,2016

2. Clonal B cells in Waldenstrom's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling;Argyropoulos;Leukemia,2016

3. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia;Treon;Blood,2014

4. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia;Yang;Blood,2013

5. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis;Hunter;Blood,2014

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events;Leukemia;2024-08-28

2. Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-07-06

3. B-cell non-Hodgkin lymphomas;The Lancet;2024-05

4. Optimizing BTK Inhibition in Waldenström Macroglobulinemia;Journal of the National Comprehensive Cancer Network;2024-05

5. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia;Blood;2024-04-25